TriLink BioTechnologies, a Maravai LifeSciences company, has entered into a non-exclusive license and supply agreement with Quantoom Biosciences to provide access to its CleanCap® mRNA capping technology. The agreement enables Quantoom to integrate CleanCap into its Ntensify® production platform for
TriLink BioTechnologies, a Maravai LifeSciences company, has signed a Memorandum of Understanding with the International Vaccine Institute (IVI) to explore joint initiatives in mRNA vaccine research, development, and equitable distribution. The agreement sets the foundation for discussions on collaborative models,
TriLink BioTechnologies, a Maravai LifeSciences company, has announced a partnership with Avantor to distribute its nucleic acid products across Europe, the Middle East, and Africa (EMEA). The collaboration aims to enhance product availability, improve ordering efficiency, and reduce lead times
TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to introduce CleanScribe™ RNA Polymerase. This novel enzyme reduces the formation of double-stranded RNA (dsRNA) by up to 85% during in vitro transcription (IVT) for mRNA production, a key
TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the opening of its new cGMP mRNA manufacturing facility in San Diego. The facility, spanning 32,000 square feet, has been specifically designed to
